Androgen deprivation and stem cell markers in prostate cancers

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 2, 2010, Pages 128-138

  Tang, Yao ^a   Hamburger, Anne W ^a   Wang, Linbo ^a   Khan, Mohammad Afnan ^a   Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation; Prostate cancer; Stem like cells; Tramp mice; Xenograft tumor

Indexed keywords

ANDROGEN; TUMOR MARKER;

ADENOCARCINOMA; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; DISEASE MODEL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; MOUSE MUTANT; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; STEM CELL; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; STEM CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951636194     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-11.
2. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66(19):9339-44.
3. Fabian A, Barok M, Vereb G, Szollosi J. Die hard: Are cancer stem cells the bruce willises of tumor biology? Cytometry A 2009;75(1):67-74.
4. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672-9.
5. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3(6):e2428.
6. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-60.
7. Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006;12(1):169-74.
8. Tang Y, Wang L, Goloubeva O, Afnan Khan M, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: Possible implications for therapy. Clin Cancer Res 2008;14(10):2936-43.
9. Tang Y, Wang L, Goloubeva O, Khan MA, Lee DI, Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. The Prostate 2009.
10. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-37.
11. Livak KJ, Schmittgen TD. Analysis of relativegene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25(4):402-8.
12. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92(8):3439-43.
13. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3):313-23.
14. Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008;6(7):1146-53.
15. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5(7):738-43.
16. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009.
17. Di Lorenzo G, Autorino R, D'Armiento FP, et al. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004;30(9):987-92.
18. Wiesner C, Nabha SM, Dos Santos EB, et al. C-kit and its ligand stem cell factor: Potential contribution to prostate cancer bone metastasis. Neoplasia 2008;10(9):996-1003.
19. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68(23):9703-11.
20. Xin L, Lawson DA, Witte ON. The sca-1 cell surface marker enriches for a prostateregenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005 [cited 2/27/2008];102(19):6942-7.
21. Lawson DA, Xin L, Lukacs R, Xu Q, Cheng D, Witte ON. Prostate stem cells and prostate cancer. Cold Spring Harb Symp Quant Biol 2005 [cited 2/27/2008];70:187-96.
22. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006;103(31):11707-12.
23. Armstrong L, Stojkovic M, Dimmick I, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004;22(7):1142-51.
24. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104(6):1648-55.
25. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006;107(5):2162-9.
26. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103(6):2332-6.
27. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1(5):555-67.
28. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40(5):499-507.
29. Walsh PC. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. J Urol 2005;173(4):1169.
30. Vezina CM, Bushman AW. Hedgehog signaling in prostate growth and benign prostate hyperplasia. Curr Urol Rep 2007;8(4):275-80.
31. Wang XD, Leow CC, Zha J, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006;290(1):66-80.
32. Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development 2004;131(20):4955-64.
33. Ceder JA, Jansson L, Ehrnstrom RA, Ronnstrand L, Abrahamsson PA. The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate. Eur Urol 2008;53(3):524-31.
34. Kim M, Turnquist H, Jackson J, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002;8(1):22-8.
35. Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 2006;26(15):5688-97.
36. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704-15.
37. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138(4):645-59.
38. Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007;117(8):2044-50.
39. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10(2):R25.